This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
Aortic stenosis is a narrowing of the aortic valve which prevents the aortic leaflets from opening and closing properly. As a result, the heart must work "over time" to pump blood throughout the body. Without treatment, up to 50% of patients will die 24 months after the onset of symptoms1.
A large new population study of men over 45 indicates insulin resistance may be an important risk factor for the development of the world's most common heartvalve disease -- aortic stenosis (AS).
A large population study of men over 45 indicates insulin resistance may be an important risk factor for the development of the world's most common heartvalve disease—aortic stenosis (AS).
IntroductionClinical evidence highlighting the efficacy and safety of transcatheter aortic valve replacement (TAVR) and the 2019 Food and Drug Administration (FDA) approval for TAVR in low-risk (younger) patients has created a demand for durable and long-lasting bioprosthetic heartvalve (BHV) leaflet materials.
IntroductionSince TAVR was approved for lower-risk aortic stenosis (AS) patients, managing post-implantation conduction disturbances has become crucial, especially with self-expanding heartvalves (SEV).
22, 2025More than 60,000 people die from heartvalve disease (HVD) in the U.S. each year, according to the American Heart Association 2025 Heart Disease and Stroke Statistical Update. This year on HeartValve Disease Awareness Day (Feb. tim.hodson Tue, 03/04/2025 - 14:11 Feb.
The global, randomized trial ( envisiontrial.com ) will evaluate the safety and effectiveness of Abbott’s minimally invasive Navitor transcatheter aortic valve implantation (TAVI) system in approximately 1,500 patients at intermediate or low surgical risk with severe aortic stenosis (narrowing of the aortic valve).
Aortic stenosis is a narrowing of the aortic valve which prevents the aortic leaflets from opening and closing properly. As a result, the heart must work "over time" to pump blood throughout the body. Without treatment, up to 50% of patients will die 24 months after the onset of symptoms1.
Findings from a published case series research letter by the Henry Ford Health Structural Heart Disease team show that severe mitral stenosis, due to a build-up of calcium deposits in the mitral valve common in elderly patients, can be safely and successfully treated using Intravascular lithotripsy (IVL)-enabled percutaneous balloon mitral valvuloplasty. (..)
These key takeaways from the research letter on IVL-facilitated valvuloplasty for severely calcified mitral valvestenosis are published in the Journal of the American College of Cardiology (JACC) Cardiovascular Interventions. an interventional cardiologist and structural heart disease expert at Henry Ford Health. “We
Some patients with aortic stenosis may require multiple valve interventions in their lifetime, and choosing transcatheter aortic valve replacement (TAVR) as the initial intervention may be appealing to many. If their transcatheter heartvalve degenerates later in life, most will hope to undergo redo-TAVR.
Food and Drug Administration (FDA) approval of its TriClip, a first-of-its-kind device to repair leaky tricuspid heartvalve, for which more than 1.6 Abbott continues to focus on addressing the unmet needs of patients with structural heart disease and advancing standards of care so people can live their fullest possible lives.
Recent findings from a study on a transcatheter heartvalve (THV) system, which includes a new class of transcatheter aortic valve, showed positive results in the device's ability to function as a healthy and natural aortic valve in patients with aortic stenosis (AS).
In all cases, patients achieved complete resolution of aortic disease with no residual stenosis or regurgitation immediately following the procedure, and all patients were discharged within 24-48 hours of the procedure.
Aortic Stenosis (AS) is a common condition with an estimated pooled prevalence of all AS in the elderly population at around 12.4%, with that of severe AS estimated to be around 3.4%. In the past, surgical aortic valve replacement was the primary treatment option for severe AS for decades.
reported results from a clinical study of revolutionary earbuds that use a new technology - In-ear Infrasonic Hemodynography to Detects Aortic Stenosis Murmur Before and After Transcatheter Aortic Valve Replacement (TAVR). This reduces or blocks blood flow from the heart to the aorta and to the rest of the body.
Transcatheter Mitral Valve Repair is Cost-Effective in Heart Failure Patients TAVR Expected to See Rapid Growth in Next 5 years FDA Clears Abbott Amplatzer Amulet LAA Occluder to Reduce Stroke in People With Atrial Fibrillation Portico TAVR System Found Safe and Effective for High-Risk Surgical Patients Portico TAVR System Reduces Severe (..)
The goal of the LANDMARK trial was to evaluate transcatheter aortic valve replacement (TAVR) with the Myval prosthesis compared with a contemporary prosthesis among patients with symptomatic severe aortic stenosis.
However, there remain several key challenges inherent in translating research on valvular heart disease to viable molecular targets that can progress through the clinical trials pathway and effectively prevent or modify the course of these common conditions.
More specifically, the Avalus Ultra surgical valve has: A low valve profile designed to facilitate ease of use at implant.1,2 Rooted in this evolving need, surgeons are demanding innovative technologies like the Avalus Ultra valve that is designed for increased ease of use and long-term durability to serve patients over their lifetime.”
BACKGROUND:Data concerning the outcomes of transcatheter aortic valve replacement in type 0 bicuspid aortic stenosis (AS) are scarce. Self-expanding transcatheter heartvalves were used in the majority of patients (n=1160; 91.4%). Circulation: Cardiovascular Interventions, Ahead of Print. Poverall=0.765; 1 year: 1.4%
Introduction Severe aortic stenosis is a major cause of morbidity and mortality. The existing treatment pathway for transcatheter aortic valve implantation (TAVI) traditionally relies on tertiary HeartValve Centre workup. Methods The centre performing local workup implemented a novel TAVI referral pathway.
More specifically, the Avalus Ultra surgical valve has: A low valve profile designed to facilitate ease of use at implant.1,2 Rooted in this evolving need, surgeons are demanding innovative technologies like the Avalus Ultra valve that is designed for increased ease of use and long-term durability to serve patients over their lifetime.”
Transcatheter aortic valve replacement (TAVR) is increasingly being performed in younger and lower surgical risk patients. Reintervention for failed transcatheter heartvalves will likely increase in the future as younger patients are expected to outlive the initial bioprosthesis.
Rates of concomitant tricuspid valve (TV) intervention at the time of left-sided heartvalve surgery were high at the time of mitral valve surgery (50% when mitral stenosis, 41% when MR). An increase in TR grade was associated with a more severe clinical presentation and a poorer 6-month survival ( p < 0.0001).
This study aimed to evaluate the feasibility of comprehensive non-contrast MRI [relaxation-enhanced angiography without contrast and triggering (REACT)] combined with a three-dimensional whole-heart MRI protocol for preprocedural planning of TAVI vs. computed tomography angiography (CTA).
All high velocity flows across the diseased valves will be shown as mosaic jets. Colour Doppler echocardiography is very useful in giving a quick visual assessment of regurgitation and stenosis of heartvalves. Stenosis of the valves can be made out by the reduced opening at the time when it is supposed to be open.
The Medtronic Evolut TAVR platform includes devices less invasive than traditional open-heart surgery for the treatment of symptomatic severe aortic stenosis. “At At Medtronic, we continue to emphasize that valve design matters. Francis Hospital , and faculty member at Columbia University. mmHg TAVR; 11.8
During the procedure, you’ll be hooked up to a heart-lung bypass machine so that your blood flow can be maintained throughout the surgery Types Of Minimally Invasive Heart Surgery If minimally invasive heart surgery is an option for you, you’ll work with a surgeon to determine the ideal one.
The authors concluded that redo-TAVR with balloon-expandable valves, may potentially represent a reasonable treatment option for selected patients with failed TAVR. For more cardiology research news join our newsletter or follow us on Twitter , Facebook , LinkedIn or Instagram.
In a remarkable leap forward for pediatric cardiac care, a groundbreaking partial heart transplant procedure has emerged as a beacon of hope for infants facing severe congenital heart conditions. This unique case presented an opportunity to utilize the heart after cardiac death through standard surgical techniques.
million people suffer from rheumatic heart disease (RHD), with an additional 47 million living with asymptomatic damage to their heartvalves, as a result of earlier acute rheumatic fever. RHD is the most commonly acquired heart disease for people under 25 years old and over 1.2 Although largely preventable, 33.4
A study led by bioengineers at the University of California San Diego sheds new light on how a type of heartvalve disease, called aortic valvestenosis, progresses differently in males and females. The research reveals that this sex-based difference can be traced to a gene on the Y chromosome.
Adult Cardiac Surgery Database Lead Author Title Publication Date Jacob Raphael Red Blood Cell Transfusion and Pulmonary Complications: The Society of Thoracic Surgeons Adult Cardiac Surgery Database Analysis The Annals of Thoracic Surgery January 2024 Joseph Sabik Multi-Arterial versus Single-Arterial Coronary Surgery: Ten Year Follow-up of One Million (..)
Institutional Coronary Artery Bypass Case Volumes and Outcomes European Journal of Heart Failure October 2023 Makoto Mori 1 Robotic Mitral Valve Repair for Degenerative Mitral Regurgitation The Annals of Thoracic Surgery August 2023 Carlos Diaz-Castrillion 2 Volume-Failure to Rescue Relationship in Acute Type A Aortic Dissections: An Analysis of The (..)
We present a case of a 76-year-old patient with concomitant severe aortic valvestenosis and severe mitral valvestenosis who underwent concurrent TAVI and transcatheter mitral valve replacement.
We organize all of the trending information in your field so you don't have to. Join thousands of users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content